McKesson Corp
MCK: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$492.00 | Gxxbk | Lwzqgdfhg |
McKesson Earnings: Strong Prescription Volume and GLP-1 Demand Reinforce Momentum
Narrow-moat McKesson reported a better-than-expected second quarter. Total sales rose 10.1% year over year as increased prescription volumes, buoyed by specialty products and GLP-1 medications (diabetes and weight loss drugs) continued to bolster the top line. We raise our fair value estimate to $400 from $394, after baking in impacts from a slightly raised full-year assumption for U.S. pharmaceutical sales and the time value of money.